GLP-1s Are About More Than Weight Loss

GLP-1 medications have become household names because of weight loss. That makes sense: weight change is visible, and it is often the reason people first hear about these medications.

But today is a good reminder that the medical story is much bigger than appearance. The FDA has approved Wegovy (semaglutide) for treatment of metabolic dysfunction-associated steatohepatitis, or MASH, in certain adults with moderate-to-advanced liver fibrosis.

This did not start with the liver

In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who also have overweight or obesity.

In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, together with reduced-calorie nutrition and increased physical activity.

And now, in August 2025, semaglutide has another important indication involving a serious metabolic liver disease.

Why this matters

These approvals do not mean that every GLP-1-based medication treats every condition, and they do not mean the medications are appropriate for everyone.

They do mean that calling these medicines simply “skinny shots” misses an increasingly important part of the picture.

The conversation I want to have with patients

When I evaluate someone for weight-management treatment, I want to know more than how many pounds they would like to lose. I want to understand the whole person: metabolic health, cardiovascular history, sleep, medications, family history, nutrition, muscle preservation, and what we are actually trying to improve.

Weight can matter medically. But it is not the only outcome that matters.

A better question than “How fast can this make me skinny?” is: “Could this treatment improve my health, and does the potential benefit outweigh the risk for me?”

That is the conversation worth having.

Sources: U.S. Food and Drug Administration announcements dated March 8, 2024; December 20, 2024; and August 15, 2025.

— Dr. Nora Phillips, DNP, APRN